0001415889-24-002379.txt : 20240202 0001415889-24-002379.hdr.sgml : 20240202 20240202175307 ACCESSION NUMBER: 0001415889-24-002379 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hannah Brendan CENTRAL INDEX KEY: 0001929422 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 24593138 MAIL ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 form4-02022024_100258.xml X0508 4 2024-02-01 0001662774 Quince Therapeutics, Inc. QNCX 0001929422 Hannah Brendan C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 273 SOUTH SAN FRANCISCO CA 94080 false true false false CHIEF BUSINESS OFFICER AND COO 0 Employee Stock Option (right to buy) 1.31 2024-02-01 4 A 0 600000 0 A 2034-01-31 Common Stock 600000 600000 D The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. /s/ Brendan Hannah 2024-02-01